丰原药业: 简式权益变动报告书（贵和达毅 ）

Core Points - The report details a share transfer agreement where Hainan Guihe Dayi Investment Partnership (Limited Partnership) acquires 23,698,554 shares of Anhui Fengyuan Pharmaceutical Co., Ltd., representing 5.1% of the company's total share capital [1][4][10] - The share transfer is based on mutual agreement between the parties involved, with the acquirer recognizing the company's future development prospects and investment value [4] - The total transfer price for the shares is approximately RMB 159.25 million, with specific amounts allocated to each transferring party [7][8] Group 1: Share Transfer Details - The share transfer agreement was signed on August 11, 2025, and involves two parties: Anhui Fengyuan Group Co., Ltd. and Ma'anshan Fengyuan Enterprise Management Co., Ltd. [5][6] - The shares being transferred are unrestricted circulating shares, with the breakdown of shares transferred being 21,464,842 from the first party and 2,233,712 from the second party [7] - The acquirer commits to not reducing its stake in the company for 18 months following the completion of the share transfer [4][10] Group 2: Compliance and Legal Aspects - The share transfer must comply with the regulations of the Shenzhen Stock Exchange and requires the completion of share transfer registration with the China Securities Depository and Clearing Corporation [2][8] - The information disclosure obligation party affirms that the report contains no false records, misleading statements, or significant omissions, and accepts legal responsibility for its accuracy [2][9] - The acquirer does not hold any other shares in listed companies that exceed 5% of their issued shares as of the report date [3]